Genor Biopharma Holdings (FRA:67N0) EBITDA Margin %: -146.01% (As of Jun. 2025)


FRA:67N0 Genor Biopharma Holdings Ltd FRA:67N0
22 GF Score
Price €0.34
! 1 Warning Sign
View Full Analysis

What is Genor Biopharma Holdings EBITDA Margin %?

Genor Biopharma Holdings FRA:67N0 +3.70% 22 EBITDA Margin % is -146.01% as of Jun. 2025. GuruFocus rates FRA:67N0 with a GF Score™ of 22/100. The stock has 1 warning sign investors should review.

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Genor Biopharma Holdings's EBITDA for the six months ended in Jun. 2025 was €-5.68 Mil. Genor Biopharma Holdings's Revenue for the six months ended in Jun. 2025 was €3.89 Mil. Therefore, Genor Biopharma Holdings's EBITDA margin for the quarter that ended in Jun. 2025 was -146.01%.

Genor Biopharma Holdings  (FRA:67N0) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.

Genor Biopharma Holdings EBITDA Margin % Related Terms

Genor Biopharma Holdings EBITDA Margin % Historical Data

* Premium members only.

The historical data trend for Genor Biopharma Holdings's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Genor Biopharma Holdings EBITDA Margin % Chart

Genor Biopharma Holdings Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
EBITDA Margin %
Get a 7-Day Free Trial -28,839.65 0.00 -4,242.84 0.00 -8.15

Genor Biopharma Holdings Semi-Annual Data
Dec18 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25
EBITDA Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 -880.14 48.15 -146.01

FRA:67N0 vs VRTX, REGN, ALNY: EBITDA Margin % Comparison

For the Biotechnology subindustry, Genor Biopharma Holdings's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Genor Biopharma Holdings EBITDA Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Genor Biopharma Holdings's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Genor Biopharma Holdings's EBITDA Margin % falls into.


FRA:67N0
22GF Score
Genor Biopharma Holdings Ltd FRA:67N0
EBITDA Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Genor Biopharma Holdings EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Genor Biopharma Holdings's EBITDA Margin % for the fiscal year that ended in Dec. 2024 is calculated as

EBITDA Margin %=EBITDA (A: Dec. 2024 )/Revenue (A: Dec. 2024 )
=-2.204/27.051
=-8.15 %

Genor Biopharma Holdings's EBITDA Margin % for the quarter that ended in Jun. 2025 is calculated as

EBITDA Margin %=EBITDA (Q: Jun. 2025 )/Revenue (Q: Jun. 2025 )
=-5.684/3.893
=-146.01 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBITDA Margin % →
What does a EBITDA Margin % of -146.01% mean?
Genor Biopharma Holdings (FRA:67N0) has a EBITDA Margin % of -146.01% as of Jun. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Genor Biopharma Holdings and its competitors.
Is Genor Biopharma Holdings' EBITDA Margin % too high?
Genor Biopharma Holdings' current EBITDA Margin % is -146.01%. Overall, Genor Biopharma Holdings has a GF Score™ of 22/100, reflecting its overall financial health beyond just this single metric.
How does Genor Biopharma Holdings' EBITDA Margin % compare to VRTX and REGN?
Genor Biopharma Holdings' EBITDA Margin % of -146.01% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Genor Biopharma Holdings and its competitors. Genor Biopharma Holdings's current EBITDA Margin % is -146.01%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Genor Biopharma Holdings stock overvalued right now?
Genor Biopharma Holdings (FRA:67N0) has a current EBITDA Margin % of -146.01%. The current EBITDA Margin % is -146.01%. Genor Biopharma Holdings' overall GF Score™ is 22/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Genor Biopharma Holdings (FRA:67N0), the current EBITDA Margin % is -146.01% as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Genor Biopharma Holdings Business Description

Address 690 Bibo Road, Room 501-02, Building 6, Pudong New District, Shanghai, CHN, 201203
Genor Biopharma Holdings Ltd is a commercial-ready biopharmaceutical company focusing on developing and commercializing oncology and autoimmune drugs. The company is focused on therapeutic areas with substantial unmet medical needs in oncology, autoimmune, and other chronic diseases. Its key drug candidates includes GB491 (lerociclib), a differentiated oral CDK4/6 inhibitor; GB221, a novel HER2 mAb drug candidate; geptanolimab (GB226), GB492, a STING agonist expected to exert synergistic effects in combination with GB226; GB242, an infliximab (Remicade) biosimilar; and GB223, a RANKL, and others.
22GF Score

Get the complete analysis for FRA:67N0

EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.34
Price